PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
SIDDHARTHA JAIN	03/12/2013
MANMOHAN SINGH	03/08/2013
DEREK O'HAGAN	03/29/2013

RECEIVING PARTY DATA

Name:	NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Street Address:	4560 HORTON STREET
City:	EMERYVILLE
State/Country:	CALIFORNIA
Postal Code:	94608-2916

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	13808245

CORRESPONDENCE DATA

Fax Number: 5106553542

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: (510) 923-2192

Email: felicia.soria@novartis.com

Correspondent Name: Helen Lee

Address Line 1: 4560 Horton Street

Address Line 2: IP Services M/S X-100B

Address Line 4: Emeryville, CALIFORNIA 94608-2916

ATTORNEY DOCKET NUMBER:	PAT054181-US-PCT
NAME OF SUBMITTER:	Felicia Soria
Signature:	/Felicia Soria/

PATENT REEL: 030216 FRAME: 0853 ,000 138082

Date:	04/15/2013	
Total Attachments: 13		
source=Signed-Asg-inventors-to-NVDInc-54	181-WO-PCT#page1.tif	
source=Signed-Asg-inventors-to-NVDInc-54	181-WO-PCT#page2.tif	
source=Signed-Asg-inventors-to-NVDInc-54	181-WO-PCT#page3.tif	
source=Signed-Asg-inventors-to-NVDInc-54	181-WO-PCT#page4.tif	
source=Signed-Asg-inventors-to-NVDInc-54181-WO-PCT#page5.tif		
source=Signed-Asg-inventors-to-NVDInc-54	181-WO-PCT#page6.tif	
source=Signed-Asg-inventors-to-NVDInc-54	181-WO-PCT#page7.tif	
source=Signed-Asg-inventors-to-NVDInc-54	181-WO-PCT#page8.tif	
source=Signed-Asg-inventors-to-NVDInc-54	181-WO-PCT#page9.tif	
source=Signed-Asg-inventors-to-NVDInc-54	181-WO-PCT#page10.tif	
source=Signed-Asg-inventors-to-NVDInc-54	181-WO-PCT#page11.tif	
source=Signed-Asg-inventors-to-NVDInc-54	181-WO-PCT#page12.tif	
source=Signed-Asg-inventors-to-NVDInc-54	181-WO-PCT#page13.tif	

Form PTO-1595 RECORDATION FOR (Rev. 07/05)			
(Rev. 07/05) PATENT: OMB No. 0651-0027 (exp. 6/30/2008)	ONLY 0.5. Patent and Hademark Onice		
	Atty Docket No.: PAT054181-WO-PCT		
To the Director of Patents and Trademarks: Please	record the attached original documents or copy thereof.		
Name of conveying party(ies):	Name and address of receiving party(ies) Name:		
SIDDHARTHA JAIN MANMOHAN SINGH	Novartis Vaccines and Diagnostics, Inc.		
DEREK O'HAGAN	4560 Horton Street Emeryville, California 94608-2916		
Additional name(s) of conveying party(ies) attached? Yes No No	94000-2910		
Assignment			
☐ Security Agreement ☐ Change of Name ☐ Joint Research Agreement ☐ Other			
Government Interest Assignment	Other		
Executive Order 9424, Confirmatory License			
Execution Date(s): 03/12/2013, 03/08/2013, 03/29/2013	Additional name(s) & address(es) attached? ☐ Yes ☒ No		
 Application number(s) or patent number(s): If this document is being filed together with a new application, the 	execution date of the annication is:		
A. Patent Application No.(s)	B. Patent No.(s)		
PCT/US2011/043086 (now 13/808,245)			
(101100201110100000 (110101101000,2110)			
Additional sumbor(e)	 attached ☐ Yes ⊠ No		
Name and address of party to whom correspondence	attached res Ø NO		
concerning document should be mailed:	Total number of applications and patents involved		
	7. Total fee (37 CFR 3.41) \$40.00		
NOVARTIS VACCINES AND DIAGNOSTICS, INC.	☐ Enclosed		
Corporate Intellectual Property – X 100B P.O. Box 8097	Authorized to be charged to deposit account,		
Emeryville, CA 94662-8097	Deposit account number: 03-1664		
	(Attach duplicate copy of this page if paying by deposit account)		
	(many angular tap, at any page n page n page n		
DO NOT USE THIS SPACE			
Statement and signature.			
To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is			
a true copy of the original document. Helen Lee, Reg. No. 39,270 // // // // // // // // // // // // //			
Name of Person Signing Signature Date			
Total number of pages including cov	er sheet, attachments, and document: 13		

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to: Mail Stop Assignment Recordation Services, Director of the USPTO, P.O. Box 1450, Alexandria, VA 22313-1450

ASSIGNMENT

This Assignment Agreement is entered into by and between Siddhartha Jain, a citizen of India, Manmohan Singh, a citizen of the United States of America, and Derek O'Hagan, a citizen of the United States of America (hereinafter "Inventor(s)"), and NOVARTIS VACCINES AND DIAGNOSTICS, INC., 4560 Horton Street, Emeryville, California 94608, a company organized under the laws of the State of Delaware.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, NOVARTIS VACCINES AND DIAGNOSTICS, INC., is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to NOVARTIS VACCINES AND DIAGNOSTICS, INC., and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of our right, title and interest for all countries of the world in and to

(1) all of our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

DELIVERY OF SELF-REPLICATING RNA USING BIODEGRADABLE POLYMER PARTICLES [Patent Case PAT054181-WO-PCT]

and filed in the United States Patent and Tradem	ark Office on	, 2013 and
accorded Application Number	-and/or filed as a PCT	International Application
on July 6, 2011 and accorded International Paten	t Application Number	PCT/US2011/043086;
and/or filed in the United States Patent and Trade	emark Office on	an d
accorded Application Number;		

- (2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);
- (3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other

applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

- (4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);
- (5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals:
- (6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;
- (7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;
- (8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates,

and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of the State of Delaware.

This Assignment is effective as from the earliest priority date as stated above.

Executed this 12 day of	 _, 2013.
Siddhartha Jain	 L.S.
Siddhartha Jain	
Kamlesh	
Witness	
Executed this day of	_,2013.
	L.S.
Manmohan Singh	
Witness	

Executed this	day of	, 2013.
		L.S.
Derek O'Hagan		
Witness		
Exposited this	day of	2012
Executed this	day of	, 2013.
NOVARTIS VAC	CCINES AND DIA	GNOSTICS, INC.
BY		L.S.
Witness		
AA 11111292		

ASSIGNMENT

This Assignment Agreement is entered into by and between Siddhartha Jain, a citizen of India, Manmohan Singh, a citizen of the United States of America, and Derek O'Hagan, a citizen of the United States of America (hereinafter "Inventor(s)"), and NOVARTIS VACCINES AND DIAGNOSTICS, INC., 4560 Horton Street, Emeryville, California 94608, a company organized under the laws of the State of Delaware.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, NOVARTIS VACCINES AND DIAGNOSTICS, INC., is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to NOVARTIS VACCINES AND DIAGNOSTICS, INC., and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of our right, title and interest for all countries of the world in and to

(1) all of our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

DELIVERY OF SELF-REPLICATING RNA USING BIODEGRADABLE POLYMER PARTICLES [Patent Case PAT054181-WO-PCT]

and filed in the United States Patent and Trad	lemark-Office on		, 2013 and
accorded Application Number	and/or filed as a PCT	International	Application
on July 6, 2011 and accorded International Pa	atent Application Number	PCT/US2011	<u>/043086;</u>
and/or filed in the United States Patent and T	rademark Office on		and
accorded Application Number			

- (2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);
- (3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other

1

applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

- (4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);
- (5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;
- (6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;
- (7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;
- (8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates,

and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of the State of Delaware.

This Assignment is effective as from the earliest priority date as stated above.

Executed this	day of		_,2013
			L.S.
Siddhartha Jain			
	O-111111111111111111111111111111111111		············
Witness			
a., 5	A		
Executed this	day of	March	_, 2013
-18L.	15 <u>1</u>	no.	L.S.
Manmohan Singh			
Jerris	KILL	N.	
Witness	A		

Executed this	day of	, 2013.
		L.S.
Derek O'Hagan		
We ye.		
Witness		
Executed this	day of	, 2013.
NOVARTIS VAC	CCINES AND DIA	GNOSTICS, INC
BY		L.S
Witness		······

ASSIGNMENT

This Assignment Agreement is entered into by and between Siddhartha Jain, a citizen of India, Manmohan Singh, a citizen of the United States of America, and Derek O'Hagan, a citizen of the United States of America (hereinafter "Inventor(s)"), and NOVARTIS VACCINES AND DIAGNOSTICS, INC., 4560 Horton Street, Emeryville, California 94608, a company organized under the laws of the State of Delaware.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, NOVARTIS VACCINES AND DIAGNOSTICS, INC., is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to NOVARTIS VACCINES AND DIAGNOSTICS, INC., and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of our right, title and interest for all countries of the world in and to

(1) all of our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

DELIVERY OF SELF-REPLICATING RNA USING BIODEGRADABLE POLYMER PARTICLES [Patent Case PAT054181-WO-PCT]

and filed in the United States Patent and Tradem	ark Office on	, 2013 and
accorded Application Number	-and/or filed as a PCT	International Application
on July 6, 2011 and accorded International Pater		PCT/US2011/043086;
and/or filed in the United States Patent and Trad	emark Office on	and
accorded Application Number ;		·

- (2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);
- (3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other

applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

- (4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);
- (5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;
- (6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;
- (7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;
- (8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates,

and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of the State of Delaware.

This Assignment is effective as from the earliest priority date as stated above.

Executed this	day of	, 2013.
		L.Ś.
Siddhartha Jain		
Witness		
Executed this	day of	, 2013.
Manmohan Singh		L.S.
Witness	·····	

Executed this 29 day of Med 32013.
Varel Off L.s.
Derek O'Hagan
Collette R. D. amica
Witness Collette R. D'Amico
Executed this 9th day of April , 2013.
NOVARTIS VACCINES AND DIAGNOSTICS, INC
BY Manual L.S
- Mitting
Li Li
Witness Feliou Soria